What must be described and justified regarding the investigational product?

• A. The trial's funding mechanism
• B. Description of and justification for the route of administration, dosage, dosage regimen, and treatment periods
• C. The schedule of monitoring visits
• D. The participant recruitment plan

Answer: (B)

Describing and justifying how the investigational product is administered—its route of administration, the exact dose, the dosage regimen, and the treatment periods—is essential because these details determine participant exposure and directly influence safety, pharmacokinetics, and how efficacy data will be interpreted. A clear dosing plan, with a rationale grounded in preclinical data, early-phase findings, and known risks, supports ethical treatment, regulatory compliance, and consistency across study sites. It also helps ensure appropriate monitoring for dose-related adverse events and allows reviewers to assess the risk–benefit balance of the trial.

The other aspects mentioned—how the trial is funded, the schedule of monitoring visits, and how participants are recruited—are important to trial conduct, but they do not specify the dosing strategy for the investigational product.